In this study, we conclude that adipocyte-specific inhibition of L-PGDS or the DP2 receptors is potentially useful for the treatment of obesity and obesity-mediated insulin resistance. Here, PTGDS is linked to obesity due to melanocortin 4 receptor deficiency.